Oligonucleotide therapeutics: manufacturing for research and beyond


It’s time for oligonucleotide therapeutics to step into the light. With an increase in therapies in preclinical and clinical stages, many therapeutic developers find that they need to scale up quickly to meet demand. 

Considering manufacturability and scale-up during small-scale method development will help deliver process efficiency and scalability, ensuring smooth technology transfer and saving time and materials. In this presentation, we’ll discuss strategies to future-proof your manufacturing for vaccines, therapeutics, and more.

Webinar Learning Objectves:

  • An overview of the current clinical landscape for oligo therapeutics
  • Key considerations for starting in-house oligonucleotide synthesis
  • Considerations for clinical scale-up

Katarina Stenklo

Enterprise Solutions Commercial Activation Leader, Cytiva

Katarina Stenklo holds a licentiate degree in biochemistry and has more than 20 years of industry experience. She currently works for Cytiva in the Manufacturing Capacity Solutions business unit. She has extensive expertise in developing end-to-end manufacturing solutions including process workflows, process equipment, automation, consumables, and facilities.
Her main focus over the last few years has been developing and designing solutions for the manufacture of new product modalities such as viral vectors, plasmids, and mRNA therapies.